About Sequence2Script

Sequence2Script is a tool to assist laboratories with translating pharmacogenomic testing results into clinically useful recommendations. The recommendations produced by this tool are based on expert guidelines developed by the Clinical Pharmacogenetics Implementation Consortium and the Royal Dutch Association for the Advancements of Pharmacy - Pharmacogenetics Working Group.

Patient Information

Specimen Information

Genetic Information

Referral Information

Sequence2Script

Sequence2Script
Pharmacogenetics Lab Test Report

Report generated: {{report_generated}}

Patient Information

Patient Name{{firstName}} {{lastName}}
Birthdate{{birthdate}}
PHN{{phn}}
Sex{{sex}}
MRN{{mrn}}

Referral Information

Referring Diagnosis{{referringDiag}}
Referring Clinician{{referringClinician}}
Referring Clinic{{labName}} {{labAddr1}} {{labAddr2}} {{city}} {{province}} {{postalCode}}

Sample Type

{{sample_type}}

Collected Date/Time

{{sCollected}}

Received Date/Time

{{sReceived}}

Patient Genetic Results

CYP2D6{{cyp2d6All1}}/{{cyp2d6All2}}{{D6Phenotype}} Metabolizer
CYP2C19{{cyp2c19All1}}/{{cyp2c19All2}}{{C19Phenotype}} Metabolizer
HLA-A*31:01-{{hlaaPn}}
HLA-B*15:02-{{hlabPn}}

Medications Affected by Patient Genetic Results

Medication NameGenes AffectedRecommendationsStrength of RecommendationSource
{{recom.name}}{{assoc}}{{recom.recommendation}}{{recom.strength}}CPIC
   

About This Report


Source of Recommendations

The recommendations made in this report are based on the recommendations provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC®, https://cpicpgx.org) and the Dutch Pharmacogenetics Working Group (DPWG, https://www.pharmgkb.org/page/dpwg). Therapeutic recommendations are based on weighing the evidence from a combination of preclinical functional and clinical data.


Strength of Recommendations

Strong: The evidence supporting the recommendation is high quality. The desirable effects clearly outweigh the undesirable effects.

Moderate: There is a close or uncertain balance as to whether the evidence for this recommendation is high quality. The desirable effects clearly outweigh the undesirable effects.

Optional: The desirable effects are closely balanced with undesirable effects, or the evidence is weak or based on extrapolations. There is room for differences in opinion as to the need for the recommended course of action.


Alleles Tested
CYP2D6*1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *14B, *15, *17, *19, *20, *29, *30, *34, *35A, *36, *38, *39, *40, *41, *42, *44, *45, *56, *57, *58, *63, *64, *65, *68, *69, *70, *71, *82, *82, *83, *84, *1xN, *2xN, *4xN, *9x2, *10x2, *17xN, *35x2
CYP2C19*1, *2, *3, *4, *5, *6, *7, *8, *12, *17
HLA-A*31:01
HLA-B*15:02

This test was performed using Agena's MassARRAY® System. This test will not detect all known mutations that result in altered gene activity. Only listed mutations are tested for and absence of a detected mutation does not rule out the possibility of sensitivity to a specific drug due to the presence of other mutations or other environmental factors.

© Sequence2Script